<DOC>
	<DOCNO>NCT00070447</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab yttrium Y 90 ibritumomab tiuxetan , locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell . Drugs use chemotherapy , prednisone , cyclophosphamide , doxorubicin , vincristine , use different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell . PURPOSE : This phase II trial study well give rituximab combination chemotherapy together yttrium Y 90 ibritumomab tiuxetan work treat patient previously untreated mantle cell lymphoma .</brief_summary>
	<brief_title>Rituximab , Prednisone , Cyclophosphamide , Doxorubicin , Vincristine , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Previously Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine time treatment failure patient previously untreated mantle cell lymphoma treat rituximab CHOP chemotherapy comprise prednisone , cyclophosphamide , doxorubicin , vincristine follow yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ; yttrium Y 90 Zevalin® ) . - Determine response rate patient completion rituximab CHOP incremental response rate IDEC-Y2B8 . - Determine toxicity regimen patient . - Correlate serum rituximab level response patient treat regimen . OUTLINE : This multicenter study . - CHOP chemotherapy rituximab : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV , rituximab IV day 1 oral prednisone day 1-5 ( R + CHOP ) . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . Patients respond stable disease proceed radioimmunotherapy . - Radioimmunotherapy : Within 4-7 week completion R + CHOP chemotherapy , patient receive rituximab IV image dose indium In 111 ibritumomab tiuxetan IV 10 minute day 1 . Patients undergo whole body gamma image scan first day ( 2-24 hour ) second third day ( 48-72 hour ) injection . In absence alter biodistribution , patient receive rituximab IV follow yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ; yttrium Y 90 Zevalin® ) IV 10 minute day 8 . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 57 patient accrue study within 2.8 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm mantle cell lymphoma expression bcl1 CD20 Stage IIIV disease Measurable evaluable disease Measurable disease define least 1 bidimensionally measurable lesion least 2 cm image scan A spleen least 17 cm discrete filling defect CT scan constitute evaluable disease provide explanation lymphomatous involvement ( e.g. , portal hypertension liver disease ) likely No known CNS lymphoma PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic WBC great 2,500/mm^3* Platelet count great 100,000/mm^3* NOTE : *Unless due disease bone marrow Hepatic Bilirubin le 1.5 mg/dL ( 1.53.0 mg/dL due liver involvement lymphoma ) ALT AST great 2.5 time upper limit normal ( unless due liver involvement lymphoma ) Renal Creatinine le 2.0 mg/dL Calcium great 11.5 mg/dL Cardiovascular LVEF great 45 % Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 year study participation HIV negative No malignancy except treated carcinoma situ cervix squamous cell basal cell skin cancer surgically cure malignancy patient diseasefree least 3 year No concurrent serious medical condition active infection would preclude ability deliver standard prednisone , cyclophosphamide , doxorubicin , vincristine ( CHOP ) chemotherapy PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy Chemotherapy No prior chemotherapy Endocrine therapy Prior corticosteroid allow provided course 2 week duration Radiotherapy No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>